


*REMARKS/ARGUMENTS*

The specification has been amended at page 1 to update the claim of priority. Claims 1-4 have been canceled. Claims 5-7 have been amended to recite "IL-21 or an agonist thereof" as supported by the specification at, for example page 8, lines 1-13. Claim 9 has been amended to depend from claim 5. Claim 5 has been amended so that each method step is distinguished by a), b), and c), as set forth in claims 18 and 21. No new matter has been added by way of these amendments.

If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



Jeremy M. Jay, Reg. No. 33,587

LEYDIG, VOIT & MAYER

700 Thirteenth Street, N.W., Suite 300

Washington, DC 20005-3960

(202) 737-6770 (telephone)

(202) 737-6776 (facsimile)

Date: May 19, 2006